Dr. Fabien Guillemot is a scientist-turned-entrepreneur, CEO, and Founder of Poietis, whose mission is to develop and market the Next-Gen Bioprinting platform to bring Tissue Engineering therapies to patients. Fabien has over 20 years of experience in the field of Biofabrication. He holds a Ph.D. in Material Science (INSA, 2000) and a Habilitation in Health and Life Sciences (Bordeaux University, 2010). He was appointed Researcher at INSERM, France in 2005, and invited researcher at Harvard University in 2010. Bioprinting pioneer and inventor (with 100+ publications and 13 patents), he left for entrepreneurship via training at HEC-Paris. Fabien will be speaking at our upcoming Bioprinting For Skin event.
Jenny: When was the first encounter you had with 3D printing?
Fabien: 2005 ! That’s cool. My thought was “how can we use it to engineer tissues?”
Jenny: What inspired you to start your journey in Bioprinting?
Jenny: What motivates you the most for your work?
Fabien: Meet unmet needs and bring new therapies to patients
Jenny: What is/are the biggest obstacle(s) in your line of work? If you have conquered them, what were your solutions?
Fabien: Make bioprinting compliant with cGMP regulation. We’ve developed the NGB-C platform, which has been recently installed in Marseille Hospital to start the first clinical trials of bioprinted autologous skin substitutes
Jenny: What do you think is (are) the biggest challenge(s) in bio-printing? What do you think the potential solution(s) is (are)?
Fabien: Dealing with tissue complexity. Tissue is not only a 3D shape. But it has biological functions which emerge from very specific microarchitecture of Cells and Extracellular Matrix components.
Jenny: If you are granted three wishes, what would they be?
Fabien: A successful first-in-human with Poieskin
More hospitals equipped with our NGB platform
Jenny: What advice would you give to a smart driven college student in the “real world”?
Fabien: Stay focused and take your time.